MediWound Ltd. has announced its financial results for the third quarter of 2026, revealing a revenue of $3.6 million. The company is currently focused on advancing its EscharEx Phase III VALUE trial, with an interim assessment and completion of enrollment expected by the end of the first quarter of 2027. This update is significant as it reflects the company's ongoing efforts to enhance its product pipeline in the competitive medicinal chemicals industry.
Founded in Yavne, Israel, MediWound Ltd. operates under the SIC classification of 2833, which pertains to Medicinal Chemicals & Botanical Products. The company trades on the Nasdaq under the ticker symbol MDWD. Recent filings include a 6-K form submitted on November 12, 2026, along with several other forms related to shareholder activities.
The filing indicates that on November 12, 2026, MediWound issued a press release titled "MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update." This press release is attached as Exhibit 99.1 to the filing. The company emphasized its strategic focus on the EscharEx Phase III VALUE trial, which is crucial for its future growth.
In the press release, CEO Ofer Gonen stated, "We continue to execute our strategic plan, with the EscharEx Phase III VALUE trial as our top priority. We are on track to complete the pre-specified interim sample size reassessment and full enrollment by the end of the first quarter of 2027." This trial is significant as it targets venous leg ulcers, a condition affecting many patients.
MediWound's financial performance has been impacted by lower revenue from development services related to U.S. government contracts. The company reported a revenue decrease from $5.4 million in Q3 2025 to $3.6 million in Q3 2026. The gross profit for the quarter was $1.0 million, reflecting a gross margin of 28.5%, an improvement from the previous year.
The company also highlighted its balance sheet strength, bolstered by $17.25 million in gross proceeds from an underwritten public offering that closed in November 2026. This funding is expected to provide MediWound with the financial flexibility needed to navigate its ongoing trials and operational expansions.
Looking ahead, MediWound's revenue outlook for 2026 remains uncertain, largely dependent on the outcome of discussions with the U.S. government regarding funding for a planned manufacturing facility. The company is actively pursuing this funding to support its growth strategy.
In addition to the EscharEx trial, MediWound is also focused on expanding its NexoBrid manufacturing capabilities. The company has reported strong demand for NexoBrid, with recent procurement under a contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) expected to continue into early 2027.
The independent Data and Safety Monitoring Board (DSMB) has completed its safety review of the VALUE trial, recommending that it continue without modification, which is a positive sign for MediWound's clinical development efforts.
As of September 30, 2026, MediWound's cash and cash equivalents totaled $28.4 million, down from $53.6 million at the end of 2025. The company reported a net loss of $6.0 million for the quarter, reflecting increased research and development expenses associated with the EscharEx trial.
In summary, MediWound Ltd. is navigating a challenging financial landscape while advancing its clinical trials and seeking government funding. The outcomes of these efforts will be critical for the company's future in the medicinal chemicals sector.
The filing does not specify what happens next, but the company has scheduled a conference call to discuss these results further.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










